INCY - Incyte Corporation logo

Incyte Corporation

INCY
Net income grew 100% of yearsRevenue grew 100% of years1Y
Compare INCY Hold

Incyte Corporation develops and commercializes biopharmaceuticals, focusing on oncology and inflammation. Its key products include JAKAFI for blood cancers, ICLUSIG for leukemia, and PEMAZYRE for biliary tract cancer, sold to pharmacies and hospitals.

โš•๏ธ Healthcare NASDAQ Listed 1993 $ USD
$1,000 invested 1 year ago โ†’$1,469today

Score Overview

1 Year
Score
Net Growth25.32%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth13.19%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score7.3
Net Growth69.98%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth94.88%
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Score
Net Growth15x
Net Trend60%
Net Income Consistency
Rev Growth426.31%
Rev TrendEvery year
Revenue Consistency
20 Years
Score6.4
Net Growth23x
Net Trend55%
Net Income Consistency
Rev Growth210x
Rev Trend90%
Revenue Consistency
30 Years
Score
Net Growth239x
Net Trend53%
Net Income Consistency
Rev Growth138x
Rev Trend80%
Revenue Consistency
All Time
Score
Net Growth331x
Net Trend55%
Net Income Consistency
Rev Growth19398x
Rev Trend81%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Incyte Corporation has ranked, year by year

Measure
Fundamentals Window

Showing 5 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • INCY

1999: 48.7% ยท 2021: 53.2% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 123.20โ€”
1 Year2025-09-29
$ 83.8946.86%
5 Years2021-09-29
$ 68.6779.41%
10 Years2016-09-29
$ 92.2933.49%
20 Years2006-09-29
$ 4.2329x
30 Years1996-09-27
$ 11.9410x
All Time1993-11-04
$ 1.8865x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 5.81B$ 1.61B$ 4.53B
2025$ 5.14B$ 1.28B$ 3.58B
2024$ 4.24B$ 32M$ 2.15B
2023$ 3.69B$ 597M$ 3.65B
2022$ 3.39B$ 340M$ 3.23B
2021$ 2.98B$ 948M$ 2.34B
2020$ 2.66B-$ 295M$ 1.80B
2019$ 2.15B$ 446M$ 2.11B
2018$ 1.88B$ 109M$ 1.43B
2017$ 1.53B-$ 313M$ 1.16B
2016$ 1.10B$ 104M$ 808M
2015$ 753M$ 6M$ 707M
2014$ 511M-$ 48M$ 600M
2013$ 354M-$ 83M$ 509M
2012$ 297M-$ 44M$ 228M
2011$ 94M-$ 186M$ 277M
2010$ 169M-$ 31M$ 424M
2009$ 9M-$ 211M$ 470M
2008$ 3M-$ 178M$ 198M
2007$ 34M-$ 86M$ 256M
2006$ 27M-$ 74M$ 318M
2005$ 7M-$ 103M$ 344M
2004$ 14M-$ 164M$ 469M
2003$ 41M-$ 166M$ 293M
2002$ 95M-$ 136M$ 429M
2001$ 219M-$ 183M$ 507M
2000$ 194M-$ 29M$ 582M
1999$ 157M-$ 26M$ 66M
1998$ 134M$ 3M$ 50M
1997$ 90M$ 6M$ 51M
1996$ 41M-$ 6M$ 7M
1995$ 12M-$ 9M$ 10M
1994-$ 11M$ 6M
IPO1993$ 300K-$ 4M$ 15M
INCY - Incyte Corporation logo

Incyte Corporation fundamental performance

Between 2020 and 2025, revenue grew from $ 2.66B to $ 5.14B and net income went from -$ 295M to $ 1.28B. Revenue increased in every one of those 5 years; net income in 3.

Between 2015 and 2025, revenue grew from $ 753M to $ 5.14B and net income grew from $ 6M to $ 1.28B. Revenue increased in every one of those 10 years; net income in 6.

Incyte Corporation currently holds a 20-year HDB Score of 6.4 out of 10. How the HDB Score is calculated.

Membership

Continue INCYโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies